在秦勤等的研究[8]中,FG被发现是一个与性别无关的独立预测心肌梗死的风险因子,在冠心病风险因子中,FG的作用超越了其他风险因素。本研究的结果显示经过PCI治疗后,应用辛伐他汀联合非诺贝特治疗的ACS病人中,FG水平比单用辛伐他汀的要低,并且在随访后的3个月中,联合降脂治疗患者的心律失常发生率要低于单纯用辛伐他汀降脂治疗组。本研究中,FG水平是否影响PCI治疗后的ACS患者的预后,还有待今后进一步的研究.
参考文献:
 [1]　Nissen SE. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL)[J]. JAMA,2004,291:1071 - 1080.
    [2]　Waters DD, Guyton JR, Herrington DM, et al. Treating to New Targets (TNT) Study: does lowering low- density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit [J]. Am J Cardi- ol,2004,93(2):154-158.
    [3]　黄善庆,麦泉云.短期应用辛伐他汀对急性冠脉综合征患 者HS-CRP的影响[J].右江民族医学院学报,2007,29 (3):377-378.
    [4]　江洪.低分子肝素联合辛伐他汀治疗不稳定型心绞痛疗 效观察[J].右江医学,2008,36(4):401-402.
    [5]　Hunninghake DB, Ballantyne CM, Maccubbin DL, et al.Comparative effects of simvastatin and atorvastatin in hyper- cholesterolemic patients with characteristics of metabolic syndrome [J]. Clin Ther,2003,25(6):1670-1686.
    [6]　Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid- lowering therapy on early mortality after acute coronary syn- dromes: an observational study [J]. Lancet, 2001, 357 (9262):1063-1068.
    [7]　Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor [J]. Am J Cardiol,2000, 86(9):943-949.
    [8]　秦勤,耿婕,崔让庄.冠心病患者血浆纤维蛋白原与小而 密低密度脂蛋白的关系[J].中华心血管病杂志,2003,31 (8):584-587.毕业论文www.lwkoo.cn    

上一页  [1] [2]